ReviewChinese medicine2022
Medicinal and edible plants in the treatment of dyslipidemia: advances and prospects.
Review in Chinese medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Evaluating the effects of seed oils on lipid profile, inflammatory and oxidative markers, and glycemic control of diabetic and dyslipidemic patients: a systematic review of clinical studies.Frontiers in nutrition · 2025Pooled it
- Effects of Melissa officinalis (lemon balm) consumption on serum lipid profile: a meta-analysis of randomized controlled trials.BMC complementary medicine and therapies · 2024Pooled it
- Effects of the combination of red yeast rice-containing commercial Chinese polyherbal preparation with statins for dyslipidemia: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Review
- Triple identity of medicinal plant-derived extracellular vesicles.Protoplasma · 2026Review
- Identification of Potential Pancreatic Lipase Inhibitors from Traditional Chinese Medicines via Molecular Docking, Molecular Dynamics Simulation and In Vitro Validation.Current issues in molecular biology · 2026Article
- Hawthorn (Molecules (Basel, Switzerland) · 2026Review
- Impacts of Herbal Medicine Use on Lipid Profiles in Type 2 Diabetic Patients in Northwest Ethiopia: A Comparative Cross-Sectional Study.BioMed research international · 2026Article
- Food-Herb Dual-Function in Astragali Radix-Poria-Rheum: Network Pharmacology and Database Mining for Diabetic Kidney Disease Mechanisms Exploration.Food science & nutrition · 2025Article
- Characterization of Bioactive Compounds inFood science & nutrition · 2025Article
- Antitumor components and mechanisms ofFrontiers in pharmacology · 2025Review
- Food and medicine homology: a potential nutritional intervention strategy for post-acute COVID-19 syndrome.Frontiers in pharmacology · 2025Review
- Article
- A medicine and food homology formula prevents cognitive deficits by inhibiting neuroinflammation and oxidative stress via activating AEA-Trpv1-Nrf2 pathway.Inflammopharmacology · 2024Article
- Research progress on the effect of medicine and food homology resources for sleep improvement.Heliyon · 2024Review
- The inhibition activity on tyrosinase, xanthine oxidase, and lipase ofFood science & nutrition · 2024Article
- Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits.Heliyon · 2024Review
- Bioactive Compounds Formulated in Phytosomes Administered as Complementary Therapy for Metabolic Disorders.International journal of molecular sciences · 2024Review
- The genomes of 5 underutilized Papilionoideae crops provide insights into root nodulation and disease resistance.GigaScience · 2024Article
- The Mechanism Underlying the Hypoglycemic Effect of Epimedin C on Mice with Type 2 Diabetes Mellitus Based on Proteomic Analysis.Nutrients · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
Dyslipidemia is an independent risk factor of cardiovascular diseases (CVDs), which lead to the high mortality, disability, and medical expenses in the worldwide. Based on the previous researches, the improvement of dyslipidemia could efficiently prevent the occurrence and progress of cardiovascular diseases. Medicinal and edible plants (MEPs) are the characteristics of Chinese medicine, and could be employed for the disease treatment and health care mostly due to their homology of medicine and food. Compared to the lipid-lowering drugs with many adverse effects, such as rhabdomyolysis and impaired liver function, MEPs exhibit the great potential in the treatment of dyslipidemia with high efficiency, good tolerance and commercial value. In this review, we would like to introduce 20 kinds of MEPs with lipid-lowering effect in the following aspects, including the source, function, active component, target and underlying mechanism, which may provide inspiration for the development of new prescription, functional food and complementary therapy for dyslipidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.